ACC 2018
Andexanet alfa: Rapid reversal of Factor Xa inhibitors
On Monday, March 12th at ACC 2018 in Orlando, Florida, an interim analysis from the ongoing ANNEXA-4 study demonstrated that the first- in-class reversal drug for direct and indirect factor Xa inhibitors, Andexanet alfa, was able to effectively reverse the anti-factor Xa activity and control major bleeding events among patients taking one of four Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban or enoxaparin). Continue reading
ACC 2018 – Wrap Up from a Pacific Rim Perspective
Dr. Daniel Scherer and Dr. Phil Aylward Discuss
Subscribe on iTunes or Google Play.
Podcast: Download
ACC 2018 Daily Wrap-Up – March 11, 2018
Dr. Ajay Kirtane and Dr. C. Michael Gibson Discuss
Subscribe on iTunes or Google Play.
Podcast: Download
